

Synthesis and Analgesic Activity of New Heterocyclic Cyanothioacetamide Derivatives

I. V. Bibik^a, E. Yu. Bibik^b, V. V. Dotsenko^{b,c,*}, K. A. Frolov^b, S. G. Krivokolysko^b, N. A. Aksenov^c,
I. V. Aksenova^c, S. V. Shcherbakov^c, and S. N. Ovcharov^c

^a Belgorod State National Research University, Belgorod, 308015 Russia

^b Kuban State University, Krasnodar, 350040 Russia

^c North Caucasus Federal University, Stavropol, 355009 Russia

*e-mail: victor_dotsenko_@mail.ru

Received December 16, 2020; revised December 16, 2020; accepted December 28, 2020

Abstract—The reaction of cyanothioacetamide with aromatic aldehydes and 1,3-dicarbonyl compounds followed by aminomethylation or *S*-alkylation gave a series of heterocyclic derivatives with a 1,2,3,4-tetrahydropyridine or 1,4,5,6,7,8-hexahydroquinoline fragment. The resulting compounds were tested for analgesic activity *in vivo*. Some of the prepared compounds showed an antinociceptive effect superior to that of ketorolac in dynamics.

Keywords: cyanothioacetamide, Mannich reaction, pyrido[2,1-*b*][1,3,5]thiadiazines, 2-oxo-3-cyano-1,4,5,6-tetrahydropyridine-2-thiolates, analgesics

DOI: 10.1134/S107036322102002X

Cyanothioacetamide **1** is a readily available and multifunctional reagent widely used in synthetic organic chemistry [1–4]. One of the main directions of the use of thioamide **1** is the preparation of a wide range of *S,N*-heterocyclic compounds, the most important of which are 3-cyanopyridine-2(1*H*)-thiones **2** [5–11] (Scheme 1). Compounds **2** are a convenient scaffolds for the synthesis of a wide range of thieno[2,3-*b*]pyridines [12–20], thiazolo[3,2-*a*]pyridines [21–29], pyrido[2,1-*b*][1,3,5]-thiadiazines [30–34], dipyrindo[1,2-*a*:1'2'-*e*][1,3,5,7]-tetrazocines [35], pyrido[1,2-*a*][1,3,5] triazines [36], isothiazolo[5,4-*b*]pyridines [37–40], and other bi- and polycyclic structures.

Many of the compounds obtained in this way exhibit valuable practical properties. In particular, pyrido[2,1-*b*]-[1,3,5]thiadiazine derivatives **3** (Scheme 2) show high activity against tick-borne encephalitis virus and Powassan virus [41], exhibit a pronounced anti-inflammatory effect [42], analeptic [43] and adaptogenic effect [44]. Disulfides **4** (Hlg = F, Br) have moderate anti-HIV activity [45], compounds **5** and **6** are inhibitors of autotaxin [46], while hexahydroquinoline **7** inhibits beta-amyloid peptide formation [47], which is considered one


of the main factors in the development of the Alzheimer's disease.

The broad spectrum of biological activity found in partially saturated nicotinonitrile derivatives readily available from α -cyanothioacetamide stimulates further research in the search for new biologically active substances in this series.


The aim of this work was to synthesize new structural analogs of compounds **3–7** and study their analgesic activity *in vivo* (rats). Cyanothioacetamide derivatives were selected for our research based on *in silico* assessment of bioavailability parameters and potential targets using open software packages OSIRIS Property Explorer [48], SwissADME [49], SwissTargetPrediction [50], Molinspiration Property Calculation Service [51], and admetSAR [52]. Thus, we selected 6 new compounds from a small (250+ compounds) library of structural analogs of **3–7**, namely pyrido[2,1-*b*][1,3,5]-thiadiazines **8a–8c**, α -(hetarylthio)acetanilides **9**, **10**, and hexahydroquinoline **11** (Scheme 3).

The syntheses of compounds **8–11** are depicted in Schemes 4–6. Thus, pyrido[2,1-*b*][1,3,5]thiadiazines **8a–8c** (Scheme 4) were prepared in 4 steps, starting

Scheme 1.




Scheme 2.



from cyanothioacetamide **1**. The reaction of thioamide **1** with 3-methoxy-4-ethoxybenzaldehyde afforded thioacrylamide **12**, which reacted without isolation with Meldrum acid **13** to form the corresponding Michael

adduct **14**. The latter underwent cyclization upon refluxing in ethanol with the elimination of acetone and CO_2 and the formation of tetrahydropyridine-2-thiolate **15**. Treatment of the latter with primary amines

Scheme 3.



in the presence of an excess of formaldehyde under mild conditions resulted in the formation of the target pyrido[2,1-*b*][1,3,5]thiadiazines **8a–8c** in high yields.

Compound **9** was synthesized by reacting cyanothioacetamide **1** with cyclohexane-1,3-dione and vanillin in three steps similar to the known procedure with intermediate isolation of mercaptoquinoline **16** [53] (Scheme 5). Hexahydroquinoline **11** was obtained by a modified method described in [54]. Finally, tetrahydropyridine **10** was prepared similar to procedure reported in [55, 56] (Scheme 6).


Compounds **8a–8c**, **9–11** are fine crystalline substances of white or beige color, poorly soluble in ethanol and diethyl ether, soluble in acetone and DMSO. Their structure was confirmed by a complex of ^1H , ^{13}C DEPTQ NMR and IR spectral data, as well as high-resolution mass spectrometry method. In addition, structure of compounds **8c** and **9** was proved using two-dimensional NMR spectroscopy methods (^1H – ^{13}C HSQC, ^1H – ^{13}C HMBC) (Tables 1, 2). The complete set of observed correlations

and signal assignments are presented in Supplementary Information.

Analgesic activity of compounds **8–11** was studied *in vivo* using the well-known thermal tail immersion test [57–60], as well as classical formalin-induced orofacial trigeminal pain test [61–65]. The average time of the tail withdrawal from a vessel with hot water in rats without pharmacological correction is 3.57 s (Table 3). Preliminary administration of ketorolac to rats of the reference group significantly increased this value to 10.92 s.

It was found that hexahydroquinolines **9** (10.15 s) and **11** (10.90 s) show the most pronounced analgesic activity. Pyrido[2,1-*b*][1,3,5]thiadiazines **8a–8c** have moderate analgesic activity and increase more than two times the tail flick time in the heat immersion test. In contrast, pyridine derivative **10** does not exhibit analgesic properties.

Data on analgesic activity in the orofacial trigeminal pain test are presented in Table 4. Thus, in 10 min we



NMM = *N*-methylmorpholine; **8** R = 4-EtC₆H₄ (**a**); 3,4-Me₂C₆H₃ (**b**); 2,4-(MeO)₂C₆H₃ (**c**).


recorded an average of 173 scratching movements of the orofacial area in rats of the control group. In 15 min this value was 250, and in 20 min—294 movements. Preliminary administration of ketorolac to rats of the reference group decreased the frequency of scratching movements by 41.04% in 10 min in comparison with the control (Table 4). A 15-min time interval after the introduction of algogen into the vibrissa region in rats of this group showed a decrease in this value by 46.6%. Within 20 min, the frequency of scratching movements decreased by 43.23% compared with the control.

Compounds **9** and **11** showed the highest analgesic activity in the orofacial trigeminal pain test already in the first 10 min, while compounds **8a** and **b** showed effect comparable to the reference drug (ketorolac). Within a 15-min interval after the administration of algogen, the


leader in analgesic activity was compound **11**, which was 19.3% more effective than ketorolac. Hexahydroquinoline derivative **9** showed an activity exceeding that of ketorolac by 14.66%. Compound **8b** exhibited activity comparable to ketorolac. Finally, within a 20-min interval after the injection of formalin solution into the vibrissa area, the maximum analgesic activity was revealed for hexahydroquinolines **9** and **11**. They exceed the reference drug in analgesic activity by 24.4 and 16.5%, respectively. The analgesic activity of compound **8b** also slightly exceeds that of ketorolac.

In the orofacial trigeminal pain test, pyridothiadiazine derivative **8c** showed low analgesic activity; we did not find significant differences in comparison with the control group of animals. Compound **10** at a similar dose did not show any analgesic effect, since at none of the

Scheme 5.




Scheme 6.



indicated time intervals this compound did not reduce the number of scratching movements. Full data on the biological activity of compounds **8–11** are presented in Supplementary Materials.

In summary, the reaction of α -cyanothioacetamide with aldehydes and 1,3-dicarbonyl compounds followed by functionalization (aminomethylation or *S*-alkylation of intermediates) provided new heterocyclic compounds

Table 1. Correlations in the ^1H - ^{13}C HSQC and ^1H - ^{13}C HMBC NMR spectra of compound **8c**

δ_{H} , ppm	δ_{C} , ppm	
	^1H - ^{13}C HSQC	^1H - ^{13}C HMBC
1.30 t (3H, OCH_2CH_3)	14.8* ($\text{CH}_3\text{CH}_2\text{O}$)	63.6 ($\text{CH}_3\text{CH}_2\text{O}$)
2.69 d. d (1H, <i>cis</i> - C^7H)	38.2 (C^7H_2)	37.3* (C^8H), 88.7 (C^9), 132.1 (C^1 C-Ar), 167.3 ($\text{C}=\text{O}$)
3.02 d. d (1H, <i>trans</i> - C^7H)	38.2 (C^7H_2)	37.3* (C^8H), 88.7 (C^9), 132.1 (C^1 C-Ar), 167.3 ($\text{C}=\text{O}$)
3.71 s (3H, MeO)	55.3* (CH_3O C-Ar)	149.0 (C^3 -OMe C-Ar)
3.74 s (3H, MeO)	55.4* (4- CH_3O N-Ar)	157.1 (C^4 -OMe N-Ar)
3.79 s (3H, MeO)	55.7* (2- CH_3O N-Ar)	152.8 (C^2 -OMe N-Ar)
3.83–3.85 m (1H, C^8H)	37.3* (C^8H)	38.2 (C^7H_2), 88.7 (C^9), 111.0* (C^2H C-Ar), 117.9 ($\text{C}\equiv\text{N}$), 132.1 (C^1 C-Ar), 149.3 (C^{9a}), 167.3 ($\text{C}=\text{O}$).
3.96 q (OCH_2CH_3)	63.6 ($\text{CH}_3\text{CH}_2\text{O}$)	14.8* ($\text{CH}_3\text{CH}_2\text{O}$), 147.3 (C^4 -OEt C-Ar)
5.10–5.28 m (4H, $\text{NCH}_2\text{NCH}_2\text{S}$)	54.7 (C^2H_2), 60.4 (C^4H_2)	54.7 (C^2H_2), 60.4 (C^4H_2), 127.3 (C^1 N-Ar), 149.3 (C^{9a}), 167.3 ($\text{C}=\text{O}$)
6.42–6.48 m (2H, H^5 N-Ar, H^6 C-Ar)	104.2* (C^5H N-Ar, 118.2* (C^6H C-Ar)	37.3* (C^8H), 100.0* (C^3H N-Ar), 111.0* (C^2H C-Ar), 127.3 (C^1 N-Ar), 147.3 (C^4 -OEt C-Ar), 157.1 (C^4 -OMe N-Ar)
6.60 d (1H, H^3 N-Ar)	100.0* (C^3H N-Ar)	104.2* (C^5H N-Ar), 127.3 (C^1 N-Ar), 152.8 (C^2 -OMe N-Ar), 157.1 (C^4 -OMe N-Ar)
6.75 d (1H, H^5 C-Ar)	112.6* (C^5H C-Ar)	132.1 (C^1 C-Ar), 149.0 (C^3 -OMe C-Ar)
6.79 d (1H, H^2 C-Ar)	111.0* (C^2H C-Ar)	37.3* (C^8H), 118.2* (C^6H C-Ar), 147.3 (C^4 -OEt C-Ar), 149.0 (C^3 -OMe C-Ar)
7.01 d (1H, H^6 N-Ar)	121.0* (C^6H N-Ar)	127.3 (C^1 N-Ar), 152.8 (C^2 -OMe N-Ar), 157.1 (C^4 -OMe N-Ar)

containing tetrahydropyridine or hexahydroquinoline fragments. The biological screening showed the presence of the most pronounced analgesic activity at a dose of 5 mg/kg exceeding that of ketorolac in two compounds, namely 2- $\{[4-(4\text{-hydroxy-3-methoxyphenyl})-5\text{-oxo-3-cyano-1,4,5,6,7,8-hexahydroquinolin-2-yl}]thio\}$ -*N*-(4-fluorophenyl)acetamide and 7,7-dimethyl-2-methylthio-4-(3,4-dimethoxyphenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile. In addition, pyrido[2,1-*b*][1,3,5]thiadiazine derivatives showed analgesic activity comparable to that of ketorolac.


EXPERIMENTAL

IR spectra were registered on a Bruker Vertex 70 spectrometer equipped with an ATR sample accessory. NMR spectra were recorded on a Bruker Avance III HD 400 MHz instrument [400.17 (^1H), 100.63 MHz (^{13}C)] using $\text{DMSO-}d_6$ as a solvent; residual solvent signals were used as a standard. High-resolution mass spectra (HRMS)

were recorded on a Bruker maXis Impact quadrupole TOF mass spectrometer using a MeCN -water system, HCO_2Na - HCO_2H calibration, and ESI-TOF ionization. Individuality of the obtained compounds was monitored by TLC on Silufol UV-254 plates, eluting with acetone-hexane mixture (1 : 1) and developing with iodine vapor or UV light.

Cyanothioacetamide **1** [66] and Meldrum's acid **13** [67] were prepared according to the known methods.

General procedure for the synthesis of 3-aryl-8-(3-methoxy-4-ethoxyphenyl)-6-oxo-2,3,4,6,7,8-hexahydropyrido[2,1-*b*][1,3,5]thiadiazine-9-carbonitriles **8a–8c.** *N*-Methylmorpholine (2 drops) was added with stirring to a mixture of 3-methoxy-4-ethoxybenzaldehyde (1.8 g, 10 mmol) and cyanothioacetamide **1** (1.0, 10 mmol) in 15 mL of ethanol. The resulting mixture was stirred until complete conversion, while the formation of a yellow-orange precipitate of the

Table 2. Correlations in the ^1H - ^{13}C HSQC and ^1H - ^{13}C HMBC NMR spectra of compound **9**

δ_{H} , ppm	δ_{C} , ppm	
	^1H - ^{13}C HSQC	^1H - ^{13}C HMBC
1.75–1.93 m (2H, C ⁷ H ₂)	20.7 (C ⁷ H ₂)	151.3 (C ^{8a}), 194.9 (C=O)
2.21–2.25 m (2H, C ⁶ H ₂)	36.7 (C ⁶ H ₂)	20.7 (C ⁷ H ₂), 26.3 (C ⁸ H ₂), 194.9 (C=O)
2.49–2.59 m (2H, C ⁸ H ₂)	26.3 (C ⁸ H ₂)	20.7 (C ⁷ H ₂), 109.2 (C ^{4a}), 151.3 (C ^{8a})
3.70 s (3H, MeO)	55.5* (OMe)	147.4 (C ⁵ -OMe Ar)
3.90 q (2H, SCH ₂)	36.8 (SCH ₂)	142.1 (C ²), 166.6 (C(O)NH)
4.40 s (1H, H ⁴)	38.6* (C ⁴ H)	92.0 (C ³), 109.2 (C ^{4a}), 111.5* (C ² H Ar), 119.4* (C ⁶ H Ar), 136.1 (C ¹ Ar), 142.1 (C ²), 151.3 (C ^{8a}), 194.9 (C=O)
6.53 d. d (1H, H ⁶ Ar)	119.4* (C ⁶ H Ar)	38.6* (C ⁴ H), 111.5* (C ² H Ar), 145.5 (C ⁴ -OH Ar)
6.64 d (1H, H ⁵ Ar)	115.4* (C ⁵ H Ar)	136.1 (C ¹ Ar), 145.5 (C ⁴ -OH Ar), 147.4 (C ⁵ -OMe Ar)
6.70 d (1H, H ² Ar)	111.5* (C ² H Ar)	38.6* (C ⁴ H), 119.4* (C ⁶ H Ar), 136.1 (C ¹ Ar), 145.5 (C ⁴ -OH Ar), 147.4 (C ⁵ -OMe Ar)
7.14–7.18 m (2H, H ³ , H ⁵ 4-FC ₆ H ₄)	115.5* d (C ³ H, C ⁵ H 4-FC ₆ H ₄)	115.5* d (C ³ H, C ⁵ H 4-FC ₆ H ₄), 134.8 d (C ¹ 4-FC ₆ H ₄), 158.3 d (C ⁴ 4-FC ₆ H ₄)
7.52–7.56 m (2H, H ² , H ⁶ 4-FC ₆ H ₄)	121.4* d (C ² H, C ⁶ H 4-FC ₆ H ₄)	121.4* d (C ² H, C ⁶ H 4-FC ₆ H ₄), 134.8 d (C ¹ 4-FC ₆ H ₄), 158.3 d (C ⁴ 4-FC ₆ H ₄)
8.86 s (1H, OH)	–	115.4* (C ⁵ H Ar), 145.5 (C ⁴ -OH Ar), 147.4 (C ⁵ -OMe Ar)
9.99 s (1H, N ¹ H)	–	26.3 (C ⁸ H ₂), 92.0 (C ³), 109.2 (C ^{4a}), 151.3 (C ^{8a})
10.39 s [1H, C(O)NH]	–	121.4* d (C ² H, C ⁶ H 4-FC ₆ H ₄), 134.8 d (C ¹ 4-FC ₆ H ₄), 166.6 [C(O)NH]

Table 3. Analgesic activity of compounds **8–11** in the test of thermal immersion of the tail in rats

Compound	Tail withdrawal time measurement results, s			
	average value	standard deviation	median value	p^a
Control	3.57	1.16	3.85	–
Ketorolac	10.92	2.36	10.10	0.03
8a	8.68	2.79	8.45	0.03
8b	9.20	4.74	10.00	0.03
8c	7.60	2.65	7.50	0.03
9	10.15	2.67	10.75	0.03
10	3.52	1.61	3.40	0.92
11	10.90	3.96	8.95	0.03

^a p —reliability of the results in comparison with the control group of animals.

Knoevenagel condensation product, 3-(3-methoxy-4-ethoxyphenyl)-2-cyanothioacrylamide **12**, was observed. To a suspension of thioacrylamide **12** were added 1.50 g (10.4 mmol) of Meldrum acid **13**, 10 mL of ethanol and 1.65 mL (15 mmol) of *N*-methylmorpholine. The

suspension was stirred until the reaction completed (control by TLC, color change from orange to white). A suspension of Michael adduct **14** was boiled with vigorous stirring until a clear yellow-orange solution was formed and then for another 30 min until the reaction was

Table 4. Analgesic activity of compounds **8–11** in the test of orofacial trigeminal pain in rats

Compound	10 min				15 min				20 min			
	average value	standard deviation	median value	p^a	average value	standard deviation	median value	p^a	average value	standard deviation	median value	p^a
Control	173.50	35.77	183.00	–	250.83	40.89	243.50	–	294.33	61.78	296.50	–
Ketorolac	102.33	20.78	98.50	0.03	133.50	34.05	124.50	0.03	166.33	45.31	167.00	0.03
8a	121.00	40.77	102.00	0.17	156.00	55.43	131.50	0.04	199.50	59.78	184.00	0.03
8b	103.17	24.60	99.50	0.03	133.83	26.92	135.00	0.03	161.67	30.50	161.00	0.03
8c	152.67	33.24	151.50	0.46	219.67	84.08	196.00	0.46	276.33	106.59	262.00	0.60
9	84.00	24.71	87.00	0.03	113.50	30.68	120.50	0.03	138.67	23.69	144.50	0.03
10	173.67	26.25	172.00	0.75	240.67	32.57	239.50	0.69	287.50	31.69	290.00	0.83
11	87.50	27.04	89.00	0.03	107.33	23.63	104.50	0.03	125.50	28.59	116.50	0.03

^a p —reliability of the results in comparison with the control group of animals.

complete. The hot reaction mixture was evaporated to 1/3 of the volume in vacuum, while *N*-methylmorpholinium 4-(3-methoxy-4-ethoxyphenyl)-6-oxo-3-cyano-1,4,5,6-tetrahydropyridine-2-thiolate **15** crystallized. Yield 2.8 g (69%), pale yellow crystals. Thiolate **15** was used without further purification. ¹H NMR spectrum, δ , ppm: 1.29 t (3H, OCH₂CH₃, ³ J = 7.0 Hz), 2.35 d. d (1H, *cis*-C⁵H, ² J = 16.1, ³ J = 4.4 Hz), 2.66 d. d (1H, *trans*-C⁵H, ² J = 16.1, ³ J = 6.9 Hz), 2.78 s (3H, NCH₃), 3.13–3.22 m (4H, CH₂NCH₂), 3.56 d. d (1H, C⁴H, ³ J = 6.9, ³ J = 4.4 Hz), 3.71 s (3H, MeO), 3.71–3.80 m (4H, CH₂OCH₂), 3.95 q (OCH₂CH₃, ³ J = 7.0 Hz), 6.64 d. d (1H, H-Ar, ³ J = 8.1, ⁴ J = 1.6 Hz), 6.78 d (1H, H-Ar, ⁴ J = 1.6 Hz), 6.83 d (1H, H-Ar, ³ J = 8.1 Hz), 8.55 br. s (1H, NH), 9.61 v. br. s (1H, NH⁺).

Thiolate **15** (0.5 g, 1.2 mmol) was dissolved by heating in 10 mL of 70% ethanol and filtered through a paper filter to obtain a clear solution. To the resulting solution was added the corresponding substituted aniline (1.2 mmol) and an excess of 37% aqueous HCHO (1 mL, 13.3 mmol). The mixture was refluxed with vigorous stirring for 2–3 min until crystallization of the reaction product, then cooled to room temperature and kept for 6 h. The precipitate was filtered off, washed with water, cooled ethanol, and diethyl ether. If necessary, it was purified by recrystallization from acetone.

8-(3-Methoxy-4-ethoxyphenyl)-3-(4-ethylphenyl)-6-oxo-2,3,4,6,7,8-hexahydropyrido[2,1-*b*][1,3,5]-thiadiazine-9-carbonitrile (8a). Yield 87%, colorless crystals. IR spectrum, ν , cm⁻¹: 2193 s (C≡N), 1691 s (C=O). ¹H NMR spectrum, δ , ppm: 1.16 t (3H, ArCH₂CH₃, ³ J = 7.6 Hz), 1.30 t (3H, OCH₂CH₃, ³ J = 7.0 Hz), 2.55 q (ArCH₂CH₃, ³ J = 7.6 Hz), 2.70 d. d (1H,

cis-C⁷H, ² J = 16.0, ³ J = 5.1 Hz), 3.00 d. d (1H, *trans*-C⁷H, ² J = 16.0, ³ J = 7.1 Hz), 3.69 s (3H, MeO), 3.80 d. d (1H, C⁸H, ³ J = 7.1, ³ J = 5.1 Hz), 3.96 q (2H, OCH₂CH₃, ³ J = 7.0 Hz), 5.33 d (1H, CH₂S, ² J = 12.5 Hz), 5.39–5.42 m (3H, CH₂NCH₂S), 6.45 d. d (1H, H-Ar, ³ J = 8.3, ⁴ J = 2.0 Hz), 6.73 d (1H, H-Ar, ³ J = 8.3 Hz), 6.78 d (1H, H-Ar, ⁴ J = 2.0 Hz), 7.00 d (2H, H-Ar, ³ J = 8.6 Hz), 7.16 d (2H, H-Ar, ³ J = 8.6 Hz). ¹³C DEPTQ NMR spectrum, δ_C , ppm: 14.8* (CH₃CH₂O), 15.6* (CH₃CH₂Ar), 27.2 (CH₃CH₂Ar), 37.4* (C⁸H), 38.1 (C⁷H₂), 52.6 (C²H₂), 55.4* (CH₃O), 57.8 (C⁴H₂), 63.6 (CH₃CH₂O), 89.3 (C⁹), 111.1* (CH Ar), 112.7* (CH Ar), 116.5* (2C, C², C⁶ 4-EtC₆H₄), 117.6 (C≡N), 128.8* (2C, C³, C⁵ 4-EtC₆H₄), 131.9 (C Ar), 136.8 (C Ar), 141.5 (C Ar), 147.3 (C⁴-OEt C-Ar), 148.8 (C³-OMe C-Ar), 149.1 (C^{9a}), 167.3 (C=O). Hereinafter, an asterisk denotes signals in antiphase. Mass spectrum (HRMS ESI-TOF), m/z : 472.1663 [M + Na]⁺ (calcd. for C₂₅H₂₇N₃NaO₃S: 472.1665), 540.1553 [M + HCOONa + Na]⁺ (calcd. for C₂₆H₂₈N₃Na₂O₅S: 540.1545).

3-(3,4-Dimethylphenyl)-8-(3-methoxy-4-ethoxyphenyl)-6-oxo-2,3,4,6,7,8-hexahydropyrido[2,1-*b*][1,3,5]thiadiazine-9-carbonitrile (8b). Yield 87%, colorless crystals. IR spectrum, ν , cm⁻¹: 2191 s (C≡N), 1689 s (C=O). ¹H NMR spectrum, δ , ppm: 1.30 t (3H, OCH₂CH₃, ³ J = 7.0 Hz), 2.16 s (3H, Me-Ar), 2.17 s (3H, Me-Ar), 2.70 d. d (1H, *cis*-C⁷H, ² J = 16.1, ³ J = 5.0 Hz), 2.99 d. d (1H, *trans*-C⁷H, ² J = 16.1, ³ J = 7.1 Hz), 3.68 s (3H, MeO), 3.79 d. d (1H, C⁸H, ³ J = 7.1, ³ J = 5.0 Hz), 3.96 q (2H, OCH₂CH₃, ³ J = 7.0 Hz), 5.29–5.44 m (4H, NCH₂NCH₂S), 6.43 d. d (1H, H-Ar, ³ J = 8.1, ⁴ J = 2.0 Hz), 6.76–6.79 m (2H, H-Ar), 6.91 d (1H, H-Ar, ⁴ J = 2.5 Hz), 7.06 d (1H, H-Ar, ³ J = 8.3 Hz). ¹³C DEPTQ NMR spectrum, δ_C , ppm: 14.8* (CH₃CH₂O), 18.4* (CH₃Ar),

19.9* (CH₃Ar), 37.4* (C⁸H), 38.1 (C⁷H₂), 52.6 (C²H₂), 55.4* (CH₃O), 57.9 (C⁴H₂), 63.6 (CH₃CH₂O), 89.1 (C⁹), 111.1* (CH Ar), 112.7* (CH Ar), 113.9* (CH Ar), 117.6 (C≡N), 117.8* (CH Ar), 118.3* (CH Ar), 129.2 (C Ar), 130.4* (CH Ar), 132.0 (C Ar), 137.2 (C Ar), 141.6 (C Ar), 147.3 (C⁴-OEt C-Ar), 148.9 (C³-OMe C-Ar), 149.1 (C^{9a}), 167.3 (C=O). Mass spectrum (HRMS ESI-TOF), *m/z*: 472.1656 [*M* + Na]⁺ (calcd. for C₂₅H₂₇N₃NaO₃S: 472.1665), 540.1520 [*M* + HCOONa + Na]⁺ (calcd. for C₂₆H₂₈N₃Na₂O₅S: 540.1545).

3-(2,4-Dimethoxyphenyl)-8-(3-methoxy-4-ethoxyphenyl)-6-oxo-2,3,4,6,7,8-hexahydropyrido[2,1-*b*]-[1,3,5]thiadiazine-9-carbonitrile (8c). Yield 91%, beige crystals. IR spectrum, *v*, cm⁻¹: 2201 s (C≡N), 1684 s (C=O). ¹H NMR spectrum, *δ*, ppm: 1.30 t (3H, OCH₂CH₃, ³*J* = 7.0 Hz), 2.69 d. d (1H, *cis*-C⁷H, ²*J* = 16.1, ³*J* = 4.8 Hz), 3.02 d. d (1H, *trans*-C⁷H, ²*J* = 16.1, ³*J* = 7.1 Hz), 3.71 s (3H, MeO), 3.74 s (3H, MeO), 3.79 s (3H, MeO), 3.83–3.85 m (1H, C⁸H), 3.96 q (2H, OCH₂CH₃, ³*J* = 7.0 Hz), 5.10–5.28 m (4H, NCH₂NCH₂S), 6.45–6.48 m (2H, H⁴ N-Ar + H⁶ C-Ar), 6.60 d (1H, H³N-Ar, ⁴*J* = 2.3 Hz), 6.75 d (1H, H⁵ C-Ar, ³*J* = 8.3 Hz), 6.79 d (1H, H² C-Ar, ⁴*J* = 1.4 Hz), 7.01 d (1H, H⁶N-Ar, ³*J* = 8.7 Hz). ¹³C DEPTQ NMR spectrum, *δ*_C, ppm: 14.8* (CH₃CH₂O), 37.3* (C⁸H), 38.2 (C⁷H₂), 54.7 (C²H₂), 55.3* (CH₃O C-Ar), 55.4* (4-CH₃O N-Ar), 55.7* (2-CH₃O N-Ar), 60.4 (C⁴H₂), 63.6 (CH₃CH₂O), 88.7 (C⁹), 100.0* (C³H N-Ar), 104.2* (C⁵HN-Ar), 111.0* (C²H C-Ar), 112.6* (C⁵H C-Ar), 117.9 (C≡N), 118.2* (C⁶H C-Ar), 121.0* (C⁶H N-Ar), 127.3 (C¹ N-Ar), 132.1 (C¹ C-Ar), 147.3 (C⁴-OEt C-Ar), 149.0 (C³-OMe C-Ar), 149.3 (C^{9a}), 152.8 (C²-OMe N-Ar), 157.1 (C⁴-OMe N-Ar), 167.3 (C=O). Mass spectrum (HRMS ESI-TOF), *m/z*: 504.1552 [*M* + Na]⁺ (calcd. for C₂₅H₂₇N₃NaO₅S: 504.1564), 572.1417 [*M* + HCOONa + Na]⁺ (calcd. for C₂₆H₂₈N₃Na₂O₇S: 572.1444).

2-[4-(4-Hydroxy-3-methoxyphenyl)-5-oxo-3-cyano-1,4,5,6,7,8-hexahydroquinolin-2-yl]thio}-*N*-(4-fluorophenyl)acetamide (9). A mixture of cyanothioacetamide **1** (2.0 g, 20 mmol), vanillin (3.04 g, 20 mmol), 25 mL of ethanol and 3 drops of piperidine was stirred until the starting reagents consumed and an orange Knoevenagel condensation product formed. To the resulting suspension were added 1,3-cyclohexanedione (2.24 g, 20 mmol) and piperidine (2.5 mL, 25 mmol). The mixture was stirred for 8 h, then acidified with 10% HCl in ethanol to pH 5. After 12 h, the precipitate was filtered off and washed with cooled alcohol. 4-(4-Hydroxy-3-

methoxyphenyl)-2-mercapto-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile **16** was obtained (yield 67%), which was used in the next step without additional purification.

To a suspension of 2-mercaptoquinoline **16** (660 mg, 2 mmol) in 15 mL of 85% ethanol were added an aqueous 10% KOH solution (1.05 mL, 2 mmol) and *N*-(4-fluorophenyl)-*α*-chloroacetamide (375 mg, 2 mmol). The resulting mixture was stirred for 12 h at 25°C. The precipitated compound **9** was filtered off and recrystallized from an acetone–ethanol mixture. Yield 86%, beige powder. IR spectrum, *v*, cm⁻¹: 3433 s, 3309 s, 3282 br, 3221 br, 3095 (O–H, N–H), 2189 s (C≡N), 1672 s (C=O), 1651 s [C(O)NH]. ¹H NMR spectrum, *δ*, ppm: 1.75–1.93 m (2H, C⁷H₂), 2.21–2.25 m (2H, C⁶H₂), 2.49–2.59 m (2H, C⁸H₂), 3.70 s (3H, MeO), 3.90 q (2H, SCH₂, ²*J* = 14.7 Hz), 4.40 s (1H, H⁴), 6.53 d. d (1H, H⁶ Ar, ³*J* = 8.1, ⁴*J* = 1.7 Hz), 6.64 d (1H, H⁵ Ar, ³*J* = 8.1 Hz), 6.70 d (1H, H² Ar, ⁴*J* = 1.7 Hz), 7.14–7.18 m (2H, H³, H⁵ 4-FC₆H₄), 7.52–7.56 m (2H, H², H⁶ 4-FC₆H₄), 8.86 s (1H, OH), 9.99 s (1H, N¹H), 10.39 s [1H, C(O)NH]. ¹³C DEPTQ NMR spectrum, *δ*_C, ppm: 20.7 (C⁷H₂), 26.3 (C⁸H₂), 36.7 (C⁶H₂), 36.8 (SCH₂), 38.6* (C⁴H), 55.5* (OMe), 92.0 (C³), 109.2 (C^{4a}), 111.5* (C²H Ar), 115.4* (C⁵H Ar), 115.5* d (C³H, C⁵H 4-FC₆H₄, ²*J*_{CF} = 22.4 Hz), 119.1 (C≡N), 119.4* (C⁶H Ar), 121.4* d (C²H, C⁶H 4-FC₆H₄, ³*J*_{CF} = 8.1 Hz), 134.8 d (C¹ 4-FC₆H₄, ⁴*J*_{CF} = 2.4 Hz), 136.1 (C¹ Ar), 142.1 (C²), 145.5 (C⁴-OH Ar), 147.4 (C⁵-OMe Ar), 151.3 (C^{8a}), 158.3 d (C⁴ 4-FC₆H₄, ¹*J*_{CF} = 240.6 Hz), 166.6 [C(O)NH], 194.9 (C=O). Mass spectrum (HRMS ESI-TOF), *m/z*: 502.1201 [*M* + Na]⁺ (calcd. for C₂₅H₂₂FN₃NaO₄S: 502.1207).

Ethyl 2-oxo-4-(2-fluorophenyl)-5-cyano-6-[(2-(2-ethylphenyl)amino)-2-oxoethyl]thio]-1,2,3,4-tetrahydropyridine-3-carboxylic acid (10). A mixture of cyanothioacetamide **1** (2.0 g, 20 mmol), 2-fluorobenzaldehyde (2.1 mL, 20 mmol), and diethylmalonate (3.05 mL, 20 mmol) was stirred in 25 mL of ethanol in the presence of an excess of *N*-methylmorpholine (25 mmol) for 7 days. The precipitate of tetrahydropyridine-2-thiolate **17** was filtered off, washed with acetone, and dried in air. Yield 44%, white powder. Thiolate **17** was used without further purification.

A mixture of thiolate **17** (2 mmol) and *α*-chloro-*N*-(2-ethylphenyl)acetamide (2 mmol) was heated in 15 mL of 85% ethanol until the starting reagents were

completely dissolved and a clear solution was formed. After 24 h, the crystallized product **10** was filtered off, washed with ethanol and petroleum ether. Yield 83%, beige powder. IR spectrum, ν , cm^{-1} : 3325 s (N–H), 2208 s (C≡N), 1732 s (C=O), 1693 s [C(O)NH], 1655 s [C(O)NH]. ^1H NMR spectrum, δ , ppm: 0.97 t (3H, ArCH₂CH₃, $^3J = 7.8$ Hz), 1.12 t (3H, OCH₂CH₃, $^3J = 7.1$ Hz), 2.59 q (2H, ArCH₂CH₃, $^3J = 7.8$ Hz), 3.97–4.04 m (5H, SCH₂, H⁴, OCH₂), 4.55 d (1H, H³, $^3J = 10.8$ Hz), 7.18–7.22 m (3H, H-Ar), 7.24–7.27 m (2H, H-Ar), 7.31–7.42 m (3H, H-Ar), 9.79 s (1H, NHAr), 11.28 s (1H, NH). ^{13}C DEPTQ NMR spectrum, δ_{C} , ppm: 13.7* (CH₃CH₂Ar), 14.83* (CH₃CH₂O), 23.6 (CH₃CH₂Ar), 35.3 (SCH₂), 36.8* d (C⁴H, $^3J_{\text{CF}} = 1.7$ Hz), 52.1* (C³), 61.2 (CH₃CH₂O), 91.2 (C⁵), 115.9* d (C³H 2-FC₆H₄, $^2J_{\text{CF}} = 21.5$ Hz), 116.7 (C≡N), 123.7 d (C¹ 2-FC₆H₄, $^2J_{\text{CF}} = 13.4$ Hz), 124.9* d (C⁵H 2-FC₆H₄, $^4J_{\text{CF}} = 3.1$ Hz), 126.01* (CH N-Ar), 126.04* (CH N-Ar), 126.3* (CH N-Ar), 128.6* (CH N-Ar), 129.6* d (C⁶H 2-FC₆H₄, $^3J_{\text{CF}} = 3.3$ Hz), 130.5* d (C⁴H 2-FC₆H₄, $^3J_{\text{CF}} = 8.4$ Hz), 134.8 (C² N-Ar), 138.2 (C¹ N-Ar), 147.2 (C⁶), 160.2 d (C² 2-FC₆H₄, $^1J_{\text{CF}} = 246.3$ Hz), 165.2 [C(O)NH], 166.8 [C(O)NH], 167.3 (CO₂Et). Mass spectrum (HRMS ESI-TOF), m/z : 504.1354 [$M + \text{Na}$]⁺ (calcd. for C₂₅H₂₄FN₃NaO₄S: 504.1364).

7,7-Dimethyl-2-methylthio-4-(3,4-dimethoxyphenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile (11). A mixture of cyanothioacetamide **1** (200 mg, 2 mmol), veratraldehyde (333 mg, 2 mmol), and piperidine (1 drop) in 5 mL of ethanol was stirred for 5 min until an orange precipitate of the Knoevenagel condensation product was formed. To the resulting suspension, dimedone (5,5-dimethylcyclohexane-1,3-dione) (280 mg, 2 mmol) and piperidine (0.25 mL, 2.5 mmol) were added with vigorous stirring. The resulting mixture was stirred until dissolved, filtered through a paper filter and kept for 24 h; in this case, the formation of a white fine-crystalline precipitate of the Michael adduct can be observed. Iodomethane (0.15 mL, 2.4 mmol) and 4 mL of 70% ethanol were added to the reaction mixture. The mixture was slowly heated to boiling with stirring, boiled for 10 min, then filtered through a paper filter and allowed to crystallize. The precipitate of quinoline **11** was filtered off, washed with ethanol, petroleum ether, and dried in air. Yield 74%, beige powder. IR spectrum, ν , cm^{-1} : 3252, 3173 w (N–H), 2195 s (C≡N), 1606 br. s (C=O, C=C). ^1H NMR spectrum, δ , ppm: 0.91 s (3H, C⁷CH₃), 1.02 s (3H, C⁷CH₃), 2.02

d (1H, C⁶H₂, $^2J = 16.4$ Hz, AB-system), 2.21 d (1H, C⁶H₂, $^2J = 16.4$ Hz, AB-system), 2.43 q (2H, C⁸H₂, $^2J = 17.6$ Hz), 2.48 s (3H, SCH₃), 3.67 s (3H, OCH₃), 3.69 s (3H, OCH₃), 4.38 s (1H, H⁴), 6.63 d. d (1H, H⁶ Ar, $^3J = 8.3$, $^4J = 2.0$ Hz), 6.69 d (1H, H² Ar, $^4J = 2.0$ Hz), 6.86 d (1H, H⁵ Ar, $^3J = 8.3$ Hz), 9.61 s (1H, NH). ^{13}C DEPTQ NMR spectrum, δ_{C} , ppm: 15.8* (SCH₃), 26.3* (C⁷CH₃), 29.1* (C⁷CH₃), 32.0 (C⁷), 38.6* (C⁴H), 39.3 (C⁸H₂), 50.1 (C⁶H₂), 55.4* (OMe), 55.5* (OMe), 90.3 (C³), 108.2 (C^{4a}), 110.8* (C²H C-Ar), 111.8* (C⁵H C-Ar), 118.95* (C⁶H C-Ar), 118.99 (C≡N), 137.7 (C¹ C-Ar), 144.5 (C^{8a}), 147.7 (COMe), 148.6 (COMe), 149.6 (C²), 194.6 (C=O). Mass spectrum (HRMS ESI-TOF), m/z : 407.1393 [$M + \text{Na}$]⁺ (calcd. for C₂₁H₂₄N₂NaO₃S: 407.1400).

The study of analgesic activity was carried out on 56 white outbred sexually mature rats of both sexes weighing 160–200 g in the autumn-winter period. Throughout the experiment, the animals were kept in a vivarium, the diet was standard, there were no more than 6 individuals in the cage, which corresponds to the guidelines for ethical review of biomedical research [68, 69]. In the pre-experimental period, a thorough examination of the animals was carried out, special attention was paid to their weight, age, physical activity and the animal coat. Based on these data, laboratory rats were evenly divided into groups: intact, control (with simulated orofacial trigeminal pain and heat tail immersion), reference (ketorolac), and 6 experimental groups according to the number of α -cyanothioacetamide derivatives studied.

Proceeding from the principles of humanity, the experiment was carried out with the minimum number of animals (6 per group) permissible for statistical processing and obtaining reliable results, as well as the minimum number of experimental groups to achieve the set goals and objectives. The assessment of analgesic activity was carried out in the test of orofacial trigeminal pain, which was simulated by the subcutaneous injection of 0.1 mL of a 5% formalin solution into the vibrissa area in laboratory rats [69]. Within 20 min (for 10, 15 and 20 min) after the introduction of algogen, the number of scratching movements with the front paws of the orofacial area was counted. Ketorolac at a dose of 0.1 mg/kg was used as a reference drug for the reference group of rats; 6 samples of the tested pyridine derivatives were injected intragastrically at a dose of 5 mg/kg 1.5 hours before the administration of the algogen (formalin) used.

To evaluate thermal pain, we chose the method of thermal tail immersion, based on the spinal flexor reflex

in response to immersion of the tail in hot water. Painful irritation was simulated by immersing the tail in a vessel with water heated to 50–54°C, while measuring the value of the latent period of the reaction. Analgesic activity was assessed by lengthening the tail flick reaction time.

The results were statistically processed using the Statistica 10.0 software package. Since the study was carried out on the smallest possible number of laboratory animals, nonparametric methods were used in the analysis of the numerical results of the experimental part of the work. In order to determine the reliability of differences in statistical data processing, a nonparametric Wilcoxon matched-pairs signed ranks test was used with preliminary determination of valid intervals of values for each of the studied indicators. In this case, the samples were assessed as continuous, sufficient in terms of the variability of the feature [70]. The significance of differences between the values of the control and experimental groups was calculated on the basis of the data obtained (median, quartile, mean values, standard deviation).

This work was performed in compliance with all applicable international, national and institutional guidelines for the care and use of animals.

FUNDING

This work was financially supported by the Kuban Science Foundation within the framework of the scientific project MFI-20.1-26/20 (application no. MFI-20.1/45), as well as the Ministry of Education and Science of the Russian Federation (topic 0795-2020-0031).

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at <https://doi.org/10.1134/S107036322102002X>.

REFERENCES

1. Abdel-Galil, F.M., Sherif, S.M., and Elnagdi, M.H., *Heterocycles*, 1986, vol. 24, no. 7, p. 2023. <https://doi.org/10.3987/R-1986-07-2023>
2. Litvinov, V.P., *Russ. Chem. Rev.*, 1999, vol. 68, no. 9, p. 737. <https://doi.org/10.1070/RC1999v068n09ABEH000533>
3. Dyachenko, V.D., Dyachenko, I.V., and Nenajdenko, V.G., *Russ. Chem. Rev.*, 2018, vol. 87, no. 1, p. 1. <https://doi.org/10.1070/RCR4760>
4. Magerramov, A.M., Shikhaliev, N.G., Dyachenko, V.D., Dyachenko, I.V., and Nenajdenko, V.G., *α -Tsyanothioacetamid* (α -Cyanothioacetamide), Moscow: Tekhnosfera, 2018.
5. Litvinov, V.P., Rodinovskaya, L.A., Sharanin, Yu.A., Shestopalov, A.M., and Senning, A., *J. Sulfur Chem.*, 1992, vol. 13, no. 1, p. 1. <https://doi.org/10.1080/01961779208048951>
6. Litvinov, V.P., *Phosphorus, Sulfur, Silicon Relat. Elem.*, 1993, vol. 74, no. 1, p. 139. <https://doi.org/10.1080/10426509308038105>
7. Litvinov, V.P., *Russ. Chem. Bull.*, 1998, vol. 47, no. 11, p. 2053. <https://doi.org/10.1007/BF02494257>
8. Litvinov, V.P., *Russ. Chem. Rev.*, 2006, vol. 75, no. 7, p. 577. <https://doi.org/10.1070/RC2006v075n07ABEH003619>
9. Litvinov, V.P., Promonenkov, V.K., Sharanin, Yu.A., and Shestopalov, A.M., *Itogi Nauki i Tekhniki. Ser. Org. Khim.*, Moscow: VINITI, 1989, vol. 17, p. 72.
10. El-Sayed, H.A., Moustafa, A.H., Said, S.A., Assy, M.G., and Amr, A.E.-G.E., *Synth. Commun.*, 2018, vol. 48, no. 20, p. 2615. <https://doi.org/10.1080/00397911.2018.1496262>
11. Salem, M.A., Helel, M.H., Gouda, M.A., Ammar, Y.A., and El-Gaby, M.S.A., *Synth. Commun.*, 2018, vol. 48, no. 4, p. 345. <https://doi.org/10.1080/00397911.2017.1394468>
12. Dotsenko, V.V., Buryi, D.S., Lukina, D.Yu., and Krivokolysko, S.G., *Russ. Chem. Bull.*, 2020, vol. 69, no. 10, p. 1829. <https://doi.org/10.1007/s11172-020-2969-2>
13. Dotsenko, V.V., Krivokolysko, S.G., Krivokolysko, B.S., and Frolov, K.A., *Russ. J. Gen. Chem.*, 2018, vol. 88, no. 4, p. 682. <https://doi.org/10.1134/S1070363218040114>
14. Buryi, D.S., Dotsenko, V.V., Aksenov, N.A., and Aksenova, I.V., *Russ. J. Gen. Chem.*, 2019, vol. 89, no. 9, p. 1744. <https://doi.org/10.1134/S1070363219090032>
15. Buryi, D.S., Dotsenko, V.V., Aksenov, N.A., Aksenova, I.V., Krivokolysko, S.G., and Dyadyuchenko, L.V., *Russ. J. Gen. Chem.*, 2019, vol. 89, no. 8, p. 1575. <https://doi.org/10.1134/S1070363219080061>
16. Chigorina, E.A., Bupalov, A.V., and Dotsenko, V.V., *Russ. J. Gen. Chem.*, 2019, vol. 89, no. 10, p. 2018. <https://doi.org/10.1134/S1070363219100062>
17. Buryi, D.S., Dotsenko, V.V., Levashov, A.S., Lukina, D.Yu., Strelkov, V.D., Aksenov, N.A., Aksenova, I.V., and Natreba, E.E., *Russ. J. Gen. Chem.*, 2019, vol. 89, no. 5, p. 886. <https://doi.org/10.1134/S1070363219050050>
18. Dotsenko, V.V., Buryi, D.S., Lukina, D.Yu., Stolyarova, A.N., Aksenov, N.A., Aksenova, I.V., Strelkov, V.D., and Dyadyuchenko, L.V., *Monatsh. Chem.*, 2019, vol. 150, no. 11, p. 1973. <https://doi.org/10.1007/s00706-019-02505-4>
19. Stroganova, T.A., Vasilin, V.K., Dotsenko, V.V., Aksenov, N.A., and Krapivin, G.D., *Tetrahedron*

- Lett.*, 2019, vol. 60, p. 997.
<https://doi.org/10.1016/j.tetlet.2019.03.012>
20. Dotsenko, V.V., Muraviev, V.S., Lukina, D.Yu., Strelkov, V.D., Aksenov, N.A., Aksenova, I.V., Krapivin, G.D., and Dyadyuchenko, L.V., *Russ. J. Gen. Chem.*, 2020, vol. 90, no. 6, p. 948.
<https://doi.org/10.1134/S1070363220060043>
21. Kažoka, H., Krauze, A., Viļums, M., Černova, L., Sīle, L., and Duburs, G., *Chem. Heterocycl. Compd.*, 2007, vol. 43, no. 1, p. 50.
<https://doi.org/10.1007/s10593-007-0007-z>
22. Kalashnik, I.N. and Dyachenko, V.D., *Russ. J. Gen. Chem.*, 2020, vol. 90, no. 3, p. 357.
<https://doi.org/10.1134/S1070363220030068>
23. Dyachenko, V.D., Matusov, I.O., Dyachenko, I.V., and Nenajdenko, V.G., *Russ. J. Org. Chem.*, 2018, vol. 54, no. 12, p. 1777.
<https://doi.org/10.1134/S1070428018120060>
24. Dotsenko, V.V., Krivokolysko, S.G., Litvinov, V.P., and Chernega, A.N., *Chem. Heterocycl. Compd.*, 2007, vol. 43, no. 5, p. 599.
<https://doi.org/10.1007/s10593-007-0094-x>
25. Krauze, A. and Duburs, G., *Chem. Heterocycl. Compd.*, 1996, vol. 32, no. 8, p. 986.
<https://doi.org/10.1007/BF01176979>
26. Dyachenko, V.D., *Russ. J. Org. Chem.*, 2007, vol. 43, no. 2, p. 271.
<https://doi.org/10.1134/S1070428007020194>
27. Shestopalov, A.M., Rodinovskaya, L.A., Sharanin, Yu.A., and Litvinov, V.P., *J. Gen. Chem. USSR*, 1988, vol. 58, no. 4, p. 745.
28. Rodinovskaya, L.A., Belukhina, E.V., Shestopalov, A.M., and Litvinov, V.P., *Russ. Chem. Bull.*, 1994, vol. 43, no. 3, p. 449.
<https://doi.org/10.1007/BF01169725>
29. Sharanin, Yu.A., Goncharenko, M.P., Shestopalov, A.M., Litvinov, V.P., and Turov, A.V., *J. Org. Chem. USSR*, 1991, vol. 27, no. 9.2, p. 1767.
30. Dotsenko, V.V., Krivokolysko, S.G., and Litvinov, V.P., *Russ. Chem. Bull.*, 2012, vol. 61, no. 1, p. 131.
<https://doi.org/10.1007/s11172-012-0018-5>
31. Frolov, K.A., Dotsenko, V.V., Krivokolysko, S.G., and Litvinov, V.P., *Chem. Heterocycl. Compd.*, 2012, vol. 48, no. 7, p. 1117.
<https://doi.org/10.1007/s10593-012-1109-9>
32. Dotsenko, V.V., Frolov, K.A., and Krivokolysko, S.G., *Chem. Heterocycl. Compd.*, 2015, vol. 51, no. 2, p. 109.
<https://doi.org/10.1007/s10593-015-1668-7>
33. Dotsenko, V.V., Frolov, K.A., Chigorina, E.A., Khrustaleva, A.N., Bibik, E.Yu., and Krivokolysko, S.G., *Russ. Chem. Bull.*, 2019, vol. 68, no. 4, p. 691.
<https://doi.org/10.1007/s11172-019-2476-5>
34. Dotsenko, V.V., Chigorina, E.A., Papaianina, E.S., Frolov, K.A., and Krivokolysko, S.G., *Macroheterocycles*, 2015, vol. 8, no. 3, p. 310.
<https://doi.org/10.6060/mhc150870d>
35. Dotsenko, V.V., Suikov, S.Yu., Pekhtereva, T.M., and Krivokolysko, S.G., *Chem. Heterocycl. Compd.*, 2013, vol. 49, no. 7, p. 1009.
<https://doi.org/10.1007/s10593-013-1339-5>
36. Dotsenko, V.V., Suikov, S.Yu., Pekhtereva, T.M., and Krivokolysko, S.G., *Chem. Heterocycl. Compd.*, 2013, vol. 49, no. 7, p. 1009.
<https://doi.org/10.1007/s10593-013-1339-5>
37. Gewald, K., Schäfer, H., and Schlegel, U., *J. Prakt. Chem.*, 1976, vol. 318, no. 5, p. 779.
<https://doi.org/10.1002/prac.19763180509>
38. Krauze, A.A., Bomika, Z.A., Pelcher, Y.É., Mazheika, I.B., and Dubur, G.Ya., *Chem. Heterocycl. Compd.*, 1982, vol. 18, no. 4, p. 385.
<https://doi.org/10.1007/BF00503559>
39. Paronikyan, E.G., Noravyan, A.S., Dzhagatspanyan, I.A., Nazaryan, I.M., and Paronikyan, R.G., *Pharm. Chem. J.*, 2002, vol. 36, no. 9, p. 465.
<https://doi.org/10.1023/A:1021836504036>
40. Moryashova, S.I., Salamandra, L.K., Fedorov, A.E., Rodinovskaya, L.A., Shestopalov, A.M., and Semenov, V.V., *Russ. Chem. Bull.*, 1998, vol. 47, no. 2, p. 357.
<https://doi.org/10.1007/BF02498968>
41. Osolodkin, D.I., Kozlovskaya, L.I., Dueva, E.V., Dotsenko, V.V., Rogova, Y.V., Frolov, K.A., Krivokolysko, S.G., Romanova, E.G., Morozov, A.S., Karganova, G.G., Palyulin, V.A., Pentkovski, V.M., and Zefirov, N.S., *ACS Med. Chem. Lett.*, 2013, vol. 4, no. 9, p. 869.
<https://doi.org/10.1021/ml400226s>
42. Bibik, E.Yu., Yaroshevskaya, O.G., Devdera, A.V., Demenko, A.V., Zakharov, V.V., Frolov, K.A., Dotsenko, V.V., and Krivokolysko, S.G., *Pharm. Chem. J.*, 2017, vol. 51, no. 8, p. 648.
<https://doi.org/10.1007/s11094-017-1669-1>
43. Bibik, E.Yu., Saphonova, A.A., Yeryomin, A.V., Frolov, K.A., Dotsenko, V.V., and Krivokolysko, S.G., *Res. Results Pharmacol.*, 2017, vol. 3, no. 4, p. 20.
<https://doi.org/10.18413/2313-8971-2017-3-4-20-25>
44. Bibik, E.Yu., Nekrasa, I.A., Demenko, A.V., Frolov, K.A., Dotsenko, V.V., and Krivokolysko, S.G., *Bull. Sib. Med.*, 2019, vol. 18, no. 3, p. 21.
<https://doi.org/10.20538/1682-0363-2019-3-21-28>
45. Rice, W.G., Turpin, J.A., Schaeffer, C.A., Graham, L., Clanton, D., Buckheit, R.W., Zaharevitz, D., Summers, M.F., Wallqvist, A., and Covell, D.G., *J. Med. Chem.*, 1996, vol. 39, no. 19, p. 3606.
<https://doi.org/10.1021/jm960375o>
46. Norman, D.D., Ibezim, A., Scott, W.E., White, S., Parrill, A.L., and Baker, D.L., *Bioorg. Med. Chem.*, 2013, vol. 21, no. 17, p. 5548.
<https://doi.org/10.1016/j.bmc.2013.05.061>

47. Mullan, M.J., Paris, D., and Bakshi, P., WO Patent 2008070875, 2008.
48. Sander, T., *OSIRIS Property Explorer*, Idorsia Pharmaceuticals Ltd., Switzerland.
<http://www.organic-chemistry.org/prog/peo/>.
49. Daina, A., Michielin, O., and Zoete, V., *Sci. Rep.*, 2017, vol. 7, Article N 42717.
<https://doi.org/10.1038/srep42717>
50. Gfeller, D., Grosdidier, A., Wirth, M., Daina, A., Michielin, O., and Zoete, V., *Nucl. Acids Res.*, 2014, vol. 42, no. W1, p. W32.
<https://doi.org/10.1093/nar/gku293>
51. Molinspiration Property Calculation Service. Molinspiration Cheminformatics, Slovak Republic, 2002.
<https://www.molinspiration.com/>.
52. Cheng, F., Li, W., Zhou, Y., Shen, J., Wu, Z., Liu, G., Lee, P.W., and Tang, Y., *J. Chem. Inf. Model.*, 2012, vol. 52, no. 11, p. 3099.
<https://doi.org/10.1021/ci300367a>
53. Litvinov, V.P., Krivokolysko, S.G., and Rusanov, E.B., *Doklady Chem.*, 2001, vol. 377, nos. 4–6, p. 94.
<https://doi.org/10.1023/A:1019205013304>
54. Krivokolysko, S.G., Dyachenko, V.D., Chernega, A.N., and Litvinov, V.P., *Russ. Chem. Bull.*, 2000, vol. 49, no. 4, p. 736.
<https://doi.org/10.1007/BF02495493>
55. Krivokolysko, S.G., Dyachenko, V.D., Nesterov, V.N., Sharanin, Yu.A., and Struchkov, Yu.T., *Russ. J. Org. Chem.*, 1999, vol. 35, no. 6, p. 942.
56. Krivokolysko, S.G., Dyachenko, V.D., and Litvinov, V.P., *Russ. Chem. Bull.*, 2000, vol. 49, no. 3, p. 487.
<https://doi.org/10.1007/BF02494780>
57. Ramabadrán, K., Bansinath, M., Turndorf, H., and Puig, M.M., *J. Pharm. Methods*, 1989, Vol. 21, no. 1, p. 21.
[https://doi.org/10.1016/0160-5402\(89\)90019-3](https://doi.org/10.1016/0160-5402(89)90019-3)
58. Sewell, R.D.E. and Spencer, P.S.J., *Neuropharmacology*, 1976, vol. 15, no. 11, p. 683.
[https://doi.org/10.1016/0028-3908\(76\)90037-X](https://doi.org/10.1016/0028-3908(76)90037-X)
59. Kotlinska, J.H., Gibula-Bruzda, E., Witkowska, E., Chung, N.N., Schiller, P.W., and Izdebski, J., *Peptides*, 2013, vol. 39, p. 103.
<https://doi.org/10.1016/j.peptides.2012.11.008>
60. Hamura, H., Yoshida, M., Shimizu, K., Matsukura, T., Suzuki, H., Narita, M., and Suzuki, T., *Jap. J. Pharmacol.*, 2000, vol. 83, no. 4, p. 286.
<https://doi.org/10.1254/jjp.83.286>
61. Raboisson, P. and Dallel, R., *Neurosci. Biobehav. Rev.*, 2004, vol. 28, no. 2, p. 219.
<https://doi.org/10.1016/j.neubiorev.2003.12.003>
62. Pereira, P.J.S., Dornelles, F.N., Santos, D.S., Calixto, J.B., Morrone, F.B., and Campos, M.M., *Int. Immunopharmacol.*, 2009, vol. 9, no. 1, p. 80.
<https://doi.org/10.1016/j.intimp.2008.10.001>
63. Le Bars, D., Gozariu, M., and Cadden, S.W., *Ann. Fr. Anesth. Reanim.*, 2001, vol. 20, no. 4, p. 347.
[https://doi.org/10.1016/S0750-7658\(01\)00381-1](https://doi.org/10.1016/S0750-7658(01)00381-1)
64. Krzyzanowska, A. and Avendaño, C., *Brain Behav.*, 2012, vol. 2, no. 5, p. 678.
<https://doi.org/10.1002/brb3.85>
65. Clavelou, P., Dallel, R., Orliaguet, T., Woda, A., and Raboisson, P., *Pain*, 1995, vol. 62, no. 3, p. 295.
[https://doi.org/10.1016/0304-3959\(94\)00273-H](https://doi.org/10.1016/0304-3959(94)00273-H)
66. Brunskill, J.S.A., De, A., and Ewing, D.F., *J. Chem. Soc. Perkin Trans. I*, 1978, no. 6, p. 629.
<https://doi.org/10.1039/P19780000629>
67. Nesterova, I.N., Shanazarov, A.K., Poznyak, A.M., Lakoza, M.I., Shemeryankin, B.V., and Granik, V.G., *Pharm. Chem. J.*, 1994, vol. 28, no. 8, p. 583.
<https://doi.org/10.1007/BF02219035>
68. Karkishchenko, N.N. and Grachev, S.V., *Al'ternativy biomeditsiny. Rukovodstvo po laboratornym zhitovnym i al'ternativnym modelyam v biomeditsinskikh tekhnologiyakh* (Iomedicine Alternatives. Guide to Laboratory Animals and Alternative Models in Biomedical Technologies), Moscow: Profil', 2010, p. 26.
69. Khabriyev, R.U., *Rukovodstvo po eksperimental'nomu (doklinicheskomu) izucheniyu novykh farmakologicheskikh sredstv* [Guidelines for Experimental (Preclinical) Study of New Pharmacological Agents], Moscow: Meditsina, 2005, p. 338.
70. Kobzar', A.I., *Prikladnaya matematicheskaya statistika* (Applied Mathematical Statistics), Moscow: Fizmatlit, 2006, p. 454.